184 related articles for article (PubMed ID: 30724002)
1. The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes.
He YL; Haynes W; Meyers CD; Amer A; Zhang Y; Mahling P; Mendonza AE; Ma S; Chutkow W; Bachman E
Diabetes Obes Metab; 2019 Jun; 21(6):1311-1321. PubMed ID: 30724002
[TBL] [Abstract][Full Text] [Related]
2. Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity.
Bays HE; Kozlovski P; Shao Q; Proot P; Keefe D
Obesity (Silver Spring); 2020 May; 28(5):870-881. PubMed ID: 32187881
[TBL] [Abstract][Full Text] [Related]
3. Glucosuric, renal and haemodynamic effects of licogliflozin, a dual inhibitor of sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2, in patients with chronic kidney disease: A randomized trial.
He Y; Pachori A; Chen P; Ma S; Mendonza AE; Amer A; Marbury TC; Hinder M
Diabetes Obes Metab; 2021 May; 23(5):1182-1190. PubMed ID: 33512754
[TBL] [Abstract][Full Text] [Related]
4. Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity.
Yokote K; Sano M; Tsumiyama I; Keefe D
Diabetes Obes Metab; 2020 Jul; 22(7):1102-1110. PubMed ID: 32072763
[TBL] [Abstract][Full Text] [Related]
5. Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure.
de Boer RA; Núñez J; Kozlovski P; Wang Y; Proot P; Keefe D
Br J Clin Pharmacol; 2020 Jul; 86(7):1346-1356. PubMed ID: 32068914
[TBL] [Abstract][Full Text] [Related]
6. Investigation and Management of Stool Frequency and Consistency Associated With SGLT1 Inhibition by Reducing Dietary Carbohydrate: A Randomized Trial.
He Y; Schofield J; Mahling P; Mendonza AE; Hinder M
Clin Pharmacol Ther; 2020 Nov; 108(5):995-1002. PubMed ID: 32236953
[TBL] [Abstract][Full Text] [Related]
7. Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial.
Tan S; Ignatenko S; Wagner F; Dokras A; Seufert J; Zwanziger D; Dunschen K; Zakaria M; Huseinovic N; Basson CT; Mahling P; Fuhrer D; Hinder M
Diabetes Obes Metab; 2021 Nov; 23(11):2595-2599. PubMed ID: 34263971
[TBL] [Abstract][Full Text] [Related]
8. Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
Zambrowicz B; Ding ZM; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Smith M; Ruff D; Sands A; Powell D
Clin Ther; 2013 Mar; 35(3):273-285.e7. PubMed ID: 23433601
[TBL] [Abstract][Full Text] [Related]
9. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.
Knop FK; Aaboe K; Vilsbøll T; Vølund A; Holst JJ; Krarup T; Madsbad S
Diabetes Obes Metab; 2012 Jun; 14(6):500-10. PubMed ID: 22171657
[TBL] [Abstract][Full Text] [Related]
10. Fructose intervention for 12 weeks does not impair glycemic control or incretin hormone responses during oral glucose or mixed meal tests in obese men.
Matikainen N; Söderlund S; Björnson E; Bogl LH; Pietiläinen KH; Hakkarainen A; Lundbom N; Eliasson B; Räsänen SM; Rivellese A; Patti L; Prinster A; Riccardi G; Després JP; Alméras N; Holst JJ; Deacon CF; Borén J; Taskinen MR
Nutr Metab Cardiovasc Dis; 2017 Jun; 27(6):534-542. PubMed ID: 28428027
[TBL] [Abstract][Full Text] [Related]
11. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.
Zambrowicz B; Ogbaa I; Frazier K; Banks P; Turnage A; Freiman J; Boehm KA; Ruff D; Powell D; Sands A
Clin Ther; 2013 Aug; 35(8):1162-1173.e8. PubMed ID: 23911260
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, metabolism, and excretion of licogliflozin, a dual inhibitor of SGLT1/2, in rats, dogs, and humans.
Wang-Lakshman L; Mendonza AE; Huber R; Walles M; He Y; Jarugula V
Xenobiotica; 2021 Apr; 51(4):413-426. PubMed ID: 33413022
[TBL] [Abstract][Full Text] [Related]
13. Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet.
Hira T; Koga T; Sasaki K; Hara H
Biochem Biophys Res Commun; 2017 Oct; 492(2):161-165. PubMed ID: 28803984
[TBL] [Abstract][Full Text] [Related]
14. Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus.
Jain M; Carlson G; Cook W; Morrow L; Petrone M; White NE; Wang T; Naylor J; Ambery P; Lee C; Hirshberg B
Diabetologia; 2019 Mar; 62(3):373-386. PubMed ID: 30593607
[TBL] [Abstract][Full Text] [Related]
15. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
16. Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study.
Harrison SA; Manghi FP; Smith WB; Alpenidze D; Aizenberg D; Klarenbeek N; Chen CY; Zuckerman E; Ravussin E; Charatcharoenwitthaya P; Cheng PN; Katchman H; Klein S; Ben-Ari Z; Mendonza AE; Zhang Y; Martic M; Ma S; Kao S; Tanner S; Pachori A; Badman MK; He Y; Ukomadu C; Sicard E
Nat Med; 2022 Jul; 28(7):1432-1438. PubMed ID: 35725922
[TBL] [Abstract][Full Text] [Related]
17. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
[TBL] [Abstract][Full Text] [Related]
18. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A
Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170
[TBL] [Abstract][Full Text] [Related]
19. Dose-dependent efficacy and safety of licogliflozin on obese adults: A systematic review and meta-analysis of randomized controlled trials.
Zaki AM; Abo-Elnour DE; Abdalla YE; Hassan RY; Salama MK; Elboraay T; Abdelhaleem IA
Diabetes Metab Syndr; 2022 Nov; 16(11):102657. PubMed ID: 36335885
[TBL] [Abstract][Full Text] [Related]
20. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
